Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sabatolimab and/or Spartalizumab with Decitabine or Azacitidine in AML/MDS
NCT03066648Phase 1Completed
- Sponsor
- Novartis
- Start
- Jul 2017
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 8
01
Overview
Phase 1, open-label trial of sabatolimab and spartalizumab in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (6 arms), sponsored by Novartis. Primary endpoints: Safety of MBG453 single agent or in combination at 24 months, Incidence of Dose Limiting Toxicities at 2 months and 1 more. Started Jul 2017; status: completed.
02
Drugs
sabatolimabspartalizumab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT03066648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03066648.